Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,249 public trials 217 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Conditions
DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) Glendale, Arizona, United States
  • Beverly Hills Cancer Center ( Site 0184) Beverly Hills, California, United States
  • Bass Medical Group ( Site 0166) Walnut Creek, California, United States
  • Innovative Clinical Research Institute ( Site 0122) Whittier, California, United States
View all 135 locations
View Trial Details
Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Infirmary Cancer Care ( Site 0157) Mobile, Alabama, United States
  • Ironwood Cancer & Research Centers ( Site 0204) Chandler, Arizona, United States
  • Palo Verde Cancer Specialists ( Site 0105) Glendale, Arizona, United States
  • City of Hope - Phoenix ( Site 0202) Goodyear, Arizona, United States
View all 139 locations
View Trial Details
Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • USA Mitchell Cancer Institute ( Site 0173) Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0165) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) Phoenix, Arizona, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0124) Tucson, Arizona, United States
View all 268 locations
View Trial Details
Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

NCT06500273

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +13 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Genesis Cancer and Blood Institute Hot Springs, Arkansas, United States
  • Alta Bates Summit Medical Center Berkeley, California, United States
  • City of Hope Duarte, California, United States
View all 82 locations
View Trial Details
Recruiting

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

NCT07424833

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +33 more
Locations
  • Mayo Clinic Jacksonville, Florida, United States
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • START Los Angele Los Angeles, California, United States
  • START Midwest Grand Rapids, Michigan, United States
View Trial Details
Recruiting

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT07197307

Conditions
Aggressive Diffuse Large B-cell Lymphoma, Follicular Lymphoma (FL) Grade 3B, Hemic and Lymphatic Diseases, +12 more
Locations
  • Universitätsklinikum Münster, Medizinische Klinik A Münster, Germany
  • Universitaetsklinikum Aachen Aachen, Germany
  • Universitaetsklinikum Augsburg Augsburg, Germany
  • Vivantes Netzwerk fuer Gesundheit Berlin, Germany
View all 34 locations
View Trial Details
Recruiting

Long-term Follow up Local Registry Study of Kymriah in South Korea

NCT06785818

Conditions
B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +17 more
Locations
  • Novartis Investigative Site Bundang Gu, Gyeonggi-do, South Korea
  • Novartis Investigative Site Seongnam-si, Gyeonggi-do, South Korea
  • Novartis Investigative Site Gyeonggi-do, Korea, South Korea
  • Novartis Investigative Site Incheon, Korea, South Korea
View all 18 locations
View Trial Details
Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606

Conditions
B-cell Non Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +21 more
Locations
  • Start Cala Los Angeles, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • NYU Langone New York, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
View all 29 locations
View Trial Details

Related conditions